AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00463541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate
Description: oral
Study NCT04141579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 MG/ML [Repatha]
Description: Evolocumab (also known as Repatha, formerly referred to as AMG 145) is a human monoclonal immunoglobulin G2 (IgG2) that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9) preventing its interaction with the low-density lipoprotein receptor (LDLR). The inhibition of PCSK9 by evolocumab leads to increased LDLR expression and subsequent decreased circulating concentrations of low-density lipoprotein cholesterol (LDL-C).
Study NCT04141579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT02145481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Decision aid describing treatment choices for patients with coronary artery disease.
Study NCT03045484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Radiotherapy were administered intensity modulated radiation therapy wiht a dose of 1.8-2.2Gy per fraction, 30-32 fraction for various tumor locations. Chemotherapy drugs platinum was used once a weak with 100mg/㎡.
Study NCT02145481 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAD Education
Description: Education for patients with coronary artery disease
Study NCT00925028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Patients of group A will have the task of managing their own warfarin therapy using the provided nomograms. In the second office visit patients will be told to which group they were randomized and if they are in group A they will then be instructed on how to use the warfarin adjustment nomograms provided. After four months the groups will switch to the alternate management strategy. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
Study NCT00925028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Patients of group B will continue to be managed by their physician. This time those in group B will be instructed on how to use the nomograms during an office visit. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
Study NCT01723553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-11 PiB
Description: One time intravenous administration of \~740 megabecquerel (MBq) of \[N-methyl-C-11\]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
Study NCT00680056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol plus Placebo (Tiotropium)
Description: Formoterol 12mcg-capsules (2x/d) + Placebo (Tiotropium) (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
Study NCT00680056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol plus Tiotropium
Description: Formoterol 12mcg-capsule (2x/dia) + Tiotropium 18mcg-capsule (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
Study NCT02552849 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03265379 — intervention group
Intervention type: OTHER
Intervention: FACT-B and Brief Pain Inventory
Description: Quality of Life Questionnaires
Study NCT00876122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0941
Description: Escalating oral dose
Study NCT01610973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endothelial descemet membrane graft
Description: Standard Endothelial descemet membrane graft
Study NCT01610973 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endothelial descemet membrane graft
Description: Standard Endothelial descemet membrane graft
Study NCT02818608 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Electrical Stimulation (FES)
Description: Functional Electrical Stimulation (FES) + Sham Transcranial direct brain stimulation (tDCS)
Study NCT02818608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combination of Transcranial direct brain stimulation (tDCS) and FES
Description: Real Functional Electrical Stimulation (FES) + Real Transcranial direct brain stimulation (tDCS)
Study NCT02928237 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation tDCS
Description: A battery driven DC stimulator (neuroConn Gmbh,98693 llmenau, Germany)
Study NCT02928237 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stimulation tDCS
Description: A battery driven DC stimulator (neuroConn Gmbh,98693 llmenau, Germany)
Study NCT04300218 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: internet-delivered cognitive-behavioral therapy for insomnia (iCBT-I)
Description: The 2-month intervention consists of educational material divided into 8 modules, which provide the rationale for the CBT-I interventions: sleep restriction; stimulus control; cognitive techniques; relaxation techniques. Information is presented in 10-minute videolectures.~The program includes a sleep diary to insert bedtime and waketime, sleep latency, total sleep time, night awakenings.~All material will be delivered through the internet program and expected to be elaborated by the patient but with the opportunity to contact a specialist via the feedback form (guidance on request) in a secured environment if they face difficulties or possible negative effects of the intervention. The content of the program is based on an already established internet-based self-help program against insomnia that was already tested in a previous study.
Study NCT04300218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive-behavioral therapy for insomnia (iCBT-I)
Description: The 2-month intervention consists of educational material divided into 8 modules, which provide the rationale for the CBT-I interventions: sleep restriction; stimulus control; cognitive techniques; relaxation techniques. Information is presented in 10-minute videolectures.~The program includes a sleep diary to insert bedtime and waketime, sleep latency, total sleep time, night awakenings.~All material will be delivered through the internet program and expected to be elaborated by the patient but with the opportunity to contact a specialist via the feedback form (guidance on request) in a secured environment if they face difficulties or possible negative effects of the intervention. The content of the program is based on an already established internet-based self-help program against insomnia that was already tested in a previous study.
Study NCT03264196 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Reduction and Internal Fixation
Description: Surgical treatment of fracture
Study NCT01305057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pyridoxine tri-isopalmitate
Description: 2% dosage, oil-in-water emulsion, twice a day, 28 days
Study NCT01150851 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: caloric restriction
Description: 10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration
Study NCT01150851 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
Study NCT00479674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death..
Study NCT00479674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg IV days 1,15 Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria,intolerable toxicity, or death.
Study NCT00479674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: area under curve (AUC)=2 IV over 15 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death.
Study NCT04877145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: drill
Description: single 3.25 mm stainless steel drill
Study NCT04877145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: drill
Description: single 3.25 mm stainless steel drill
Study NCT01071265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: Occlusion of leg blood flow using a pneumatic tourniquet on the thigh. Tourniquets are inflated to 300 mmHg for 5 minutes followed by deflation for 5 minutes then repeated for a total of 3 inflations.
Study NCT01071265 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: Sham procedure. A pneumatic tourniquet is placed on an upper arm and/or thigh but not inflated.
Study NCT00754858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belotecan hydrochloride
Study NCT00754858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00837564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBASP psychotherapy
Description: specific psychotherapy for chronic depression
Study NCT03505411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin supplementation
Study NCT04212481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uniport video-assisted thoracoscopic surgery
Description: video-assisted thoracoscopic surgery for NSCLC using single port or two ports or three ports
Study NCT04212481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: two ports video-assisted thoracoscopic surgery
Description: video-assisted thoracoscopic surgery for NSCLC using two ports
Study NCT04212481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: three ports video-assisted thoracoscopic surgery
Description: video-assisted thoracoscopic surgery for NSCLC using three ports
Study NCT02117544 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lenses (new)
Study NCT02117544 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lenses
Study NCT02059161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1293
Description: MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
Study NCT02059161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus™
Description: Lantus™ dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
Study NCT02059161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prandial Insulin
Description: Participants will continue their prandial insulin during the study.
Study NCT02059161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prandial Insulin
Description: Participants will continue their prandial insulin during the study.
Study NCT03293485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem+Cilastatin/Relebactam
Description: Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, 30-minute IV infusion once every 6 hours
Study NCT01171365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: Inhaled ciclesonide 320mcg twice daily
Study NCT01171365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo inhaler two inhalations twice daily
Study NCT00372528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin (LYRICA)
Description: 150 mg up to a maximum of 600 mg per day bid or tid as required
Study NCT00949962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiandrogen therapy
Description: Given systemically
Study NCT00949962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: Given subcutaneously
Study NCT00949962 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo radiotherapy
Study NCT00949962 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: Undergo radiotherapy
Study NCT02726178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advil® Pediatric drops for infants
Description: Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
Study NCT02726178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
Study NCT04300218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual (CAU)
Description: Intervention includes all variety of therapy methods that can be prescribed by medical doctors (MD): pharmacotherapy, behavioral recommendations, face-to-face psychotherapy. Prescriptions may be made during the first visit to MD, or at any point in the study on a next doctor visit, or during visits to the doctors of other medical centers. All concurrently applied treatments will be assessed repeatedly by self-report
Study NCT04300218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care as usual (CAU)
Description: Intervention includes all variety of therapy methods that can be prescribed by medical doctors (MD): pharmacotherapy, behavioral recommendations, face-to-face psychotherapy. Prescriptions may be made during the first visit to MD, or at any point in the study on a next doctor visit, or during visits to the doctors of other medical centers. All concurrently applied treatments will be assessed repeatedly by self-report
Study NCT01511146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin 85 mg/m2 in 10 minutes
Study NCT01511146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin + Gemcitabine
Description: Mitomycin 5 mg/m2 Gemcitabine 1000 mg/m2
Study NCT03977389 — intervention group
Intervention type: PROCEDURE
Intervention: Total wrist denervation
Description: Study of the files
Study NCT02137551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ABM
Description: The ABM involves synchronizing all medications to come due on the same say of the month and the individual receives a pre-appointment phone call from the pharmacy staff to review medications and identify any changes.
Study NCT03725046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized information transmission
Description: Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
Study NCT02556879 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Donor specific antibodies
Description: Additional samples for Donor specific antibodies at each visit
Study NCT02556879 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Serum bank
Description: Additional samples for serum bank at each visit if possible
Study NCT02556879 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DNA bank
Description: Additional sample for DNA bank at inclusion visit if possible
Study NCT02556879 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liver biopsy
Description: Liver biopsy at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
Study NCT02556879 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Liver ultrasounds and Fibroscan
Description: Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
Study NCT01301612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab, 200 mg, IV, Weekly doses for 14 weeks
Study NCT01301612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks
Study NCT01301612 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Brachytherapy: 40 Gy at spot A(low dose rate, Intracavitary, 1 or 2 separate fractions for 1 to 3 weeks.~Brachytherapy: 28 Gy at spot A (high dose rate), Intracavitary 4 fractions of 7.0 Gy once or twice a week.
Study NCT01301612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin, 40 mg/m2, IV. Weekly doses for 6 weeks
Study NCT01301612 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Pelvic radiation therapy: 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.~Dose boosts: 15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week.~Brachytherapy 40 Gy at spot A(low dose rate.) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks.~28 Gy at spot A (high dose rate, Intracavitary, 4 fractions of 7.0 Gy once or twice a week
Study NCT01950884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe tablets
Study NCT01950884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle
Description: lifestyle
Study NCT01950884 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: lifestyle
Study NCT03634072 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PVR
Description: Subjects will undergo PVR via surgery or cardiac catheterization. PVR using cardiac catheterization may require a much shorter hospital stay than traditional heart surgery. If the valve is repaired by surgery, this will require open heart surgery to directly implant a pulmonary valve
Study NCT04115397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Treating seropositive individuals with musculoskeletal symptoms with one infusion zolendronic acid as compared to placebo
Study NCT04115397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00778323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: limb remote ischemic preconditioning (LRIPC)
Description: LRIPC consists of three 5-min cycles of right upper limb ischemia induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mmHg,with an intervening 5 min reperfusion during which the cuff is deflated.
Study NCT00856427 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy treatment planning/simulation
Description: Undergo implantation of radio-opaque markers
Study NCT00856427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implanted fiducial-based imaging
Description: Undergo implantation of radio-opaque markers
Study NCT03714412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: Implantation of the Cardiovalve transfemoral mitral valve replacement system
Study NCT03575468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced E-cigarette Coaching
Description: The EEC intervention calls will include assessment of e-cigarette use and discussion about how and why e-cigarettes are being used on every call. In addition to the standard quitline cessation program, the enhanced program will include education (via quit coaches and two tailored quit guides), behavioral support tailored to dual users, and shared decision making strategies to address how and why FDA-approved quitting aids and ENDS are being used and to develop an integrated quit plan based on callers' decisions.